BRPI0407578A - derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização - Google Patents

derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização

Info

Publication number
BRPI0407578A
BRPI0407578A BRPI0407578-1A BRPI0407578A BRPI0407578A BR PI0407578 A BRPI0407578 A BR PI0407578A BR PI0407578 A BRPI0407578 A BR PI0407578A BR PI0407578 A BRPI0407578 A BR PI0407578A
Authority
BR
Brazil
Prior art keywords
optionally substituted
alkyl
aryl
upto
dioxolyl
Prior art date
Application number
BRPI0407578-1A
Other languages
English (en)
Inventor
Florence Bordon-Pallier
Jean-Luc Haesslein
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0407578A publication Critical patent/BRPI0407578A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DERIVADOS DA PURINA, SEU PROCESSO DE PREPARAçãO, SUA APLICAçãO A TìTULO DE MEDICAMENTOS, COMPOSIçõES FARMACêUTICAS E UTILIZAçãO". A invenção refere-se os novos produtos de fórmula (I), na qual: Y representa N, O, S, CHR3 ou =CR3 a linha em pontilhado representando uma ligação simples ou dupla, R e R1 representam H, Hal, OH, alquila, alcóxi, ciano, NO2, NR4R5, trifluorometila, trifluorometóxi, arila, heteroarila, -S(O)n-NR4R5, com n representando de 0 a 2, acila, -NH-CO-alquila ou -NH-CO-NH-fenila, R3 representa H, Hal, alquila, ciano, NO2, NR4R5, trifluorometila ou arila R2 representa R4, OR4, SR4 ou NR4R5, R4 representa um H, alquila, cicloalquila ou arila, seja R4 e R5 são escolhidos dentre os valores de R4, seja R4 e R5 formam com N um radical heterocíclico podendo conter N, O e S, todos esses radicais sendo eventualmente sendo substituídos, estando esses produtos sob todas as formas isómeras e os sais, a título de medicamentos.
BRPI0407578-1A 2003-02-18 2004-02-13 derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização BRPI0407578A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301915A FR2851248B1 (fr) 2003-02-18 2003-02-18 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
PCT/FR2004/000330 WO2004073595A2 (fr) 2003-02-18 2004-02-13 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Publications (1)

Publication Number Publication Date
BRPI0407578A true BRPI0407578A (pt) 2006-02-14

Family

ID=32749627

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407578-1A BRPI0407578A (pt) 2003-02-18 2004-02-13 derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização

Country Status (11)

Country Link
EP (1) EP1597258B1 (pt)
JP (1) JP2006517955A (pt)
AT (1) ATE413401T1 (pt)
AU (1) AU2004212733B2 (pt)
BR (1) BRPI0407578A (pt)
CA (1) CA2515610A1 (pt)
DE (1) DE602004017580D1 (pt)
FR (1) FR2851248B1 (pt)
IL (1) IL170318A (pt)
MX (1) MXPA05007519A (pt)
WO (1) WO2004073595A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
GB0519245D0 (en) * 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
CA2672213C (en) * 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
JP2010526027A (ja) * 2007-01-23 2010-07-29 パラウ・フアルマ・ソシエダツド・アノニマ プリン誘導体
EP2134723B1 (en) 2007-03-07 2017-07-12 Boehringer Ingelheim International GmbH 2,6 diamino-9h-purine derivatives and their use in the treatment of proliferative diseases
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
AU2009269087A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc PI3K isoform selective inhibitors
WO2013123215A2 (en) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
RU2760305C1 (ru) * 2021-04-26 2021-11-23 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) 4-[(Пурин-6-ил)аминополиметиленкарбонил]-производные 3,4-дигидро-3-метил-7,8-дифтор-2H-[1,4]бензоксазина, обладающие противоопухолевой активностью

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
DE69531558T2 (de) * 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
WO2000044750A1 (en) * 1999-02-01 2000-08-03 Cv Therapeutics, Inc. PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a)
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MXPA03003774A (es) * 2000-10-31 2003-07-28 Aventis Pharm Prod Inc Derivados de acilo y sulfonilo de 2-(trans-1, 4-diaminociclohexil)-purinas 6,9-disubstituidas y sus uso como agentes antiproliferativos.
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
WO2004073595A3 (fr) 2005-01-06
WO2004073595A2 (fr) 2004-09-02
EP1597258B1 (fr) 2008-11-05
FR2851248B1 (fr) 2005-04-08
DE602004017580D1 (de) 2008-12-18
JP2006517955A (ja) 2006-08-03
FR2851248A1 (fr) 2004-08-20
CA2515610A1 (fr) 2004-09-02
ATE413401T1 (de) 2008-11-15
AU2004212733A1 (en) 2004-09-02
IL170318A (en) 2011-02-28
EP1597258A2 (fr) 2005-11-23
MXPA05007519A (es) 2005-09-21
AU2004212733B2 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
DE69027440D1 (de) Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
BRPI0407578A (pt) derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização
DE69627035D1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
NO308798B1 (no) Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
BR0109469A (pt) Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto
DE60238999D1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE175201T1 (de) Mono-n-substituierte 1,4,7,10- tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BRPI0614168A2 (pt) Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto
BR9609617B1 (pt) derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
CA2379560A1 (en) Purine derivatives inhibitors of tyrosine protein kinase syk
DE69412109D1 (de) Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
DK0783501T3 (da) Pyrimidonderivater med anti-fungal aktivitet
AR040580A1 (es) Derivados de pirazol heterobiciclico como inhibidores de la quinasa
DK0773943T3 (da) Forbindelser, der er anvendelige som antiproliferative midler og garft-inhibitorer
DK0587087T3 (da) Substituerede cyclohexan-derivater til behandling af sygdomme
ES2138983T3 (es) Uso de derivados del acido 2-(n-(2-aminoetil)amino)-acetico para el tratamiento de enfermedades condicionadas por glicosilacion no enzimatica.
FI951858A0 (fi) Kinoloni- ja akridonijohdannaisia virtsanpidätyskyvyttömyyden hoidossa
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
ATE105838T1 (de) 6-fluor-3,5-dihydroxycarbonsäuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische präparate und zwischenprodukte.
ATE119149T1 (de) Pyrrolidonderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.